The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10660 malaria professionals are enjoying the free benefits of MalariaWorld today

lumefantrine

Pharmacology: Population Pharmacokinetics and Pharmacodynamics of Artemether and Lumefantrine during Combination Treatment in Children with Uncomplicated Falciparum Malaria in Tanzania

October 18, 2010 - 09:40 -- Patrick Sampao
Author(s): 
Sofia F., Andreas M., et al.
Reference: 
Antimicrob. Agents Chemother., Nov 2010; 54: 4780 - 4788.

The aim of this analysis was to describe the pharmacokinetics and pharmacodynamics of artemether, dihydroartemisinin, and lumefantrine in African children with uncomplicated malaria.

Person: 
Medical Condition: 
Medical Treatment: 

In Vitro Activities of Piperaquine, Lumefantrine, and Dihydroartemisinin in Kenyan Plasmodium falciparum Isolates and Polymorphisms in pfcrt and pfmdr1

December 7, 2009 - 12:03 -- Ingeborg van Schayk
Author(s): 
Leah Mwai, Steven M. Kiara, Abdi Abdirahman, Lewa Pole, Anja Rippert, Abdi Diriye, Pete Bull, Kevin Marsh, Steffen Borrmann, and Alexis Nzila
Reference: 
Antimicrob. Agents Chemother. 2009;53 5069-5073

We have analyzed the in vitro chemosensitivity profiles of 115 Kenyan isolates for chloroquine (CQ), piperaquine, lumefantrine (LM), and dihydroartemisinin in association with polymorphisms in pfcrt at codon 76 and pfmdr1 at codon 86, as well as with variations of the copy number of pfmdr1.

Technology: 
Country: 
Medical Condition: 

In Vitro Activities of Piperaquine, Lumefantrine, and Dihydroartemisinin in Kenyan Plasmodium falciparum Isolates and Polymorphisms in pfcrt and pfmdr1.

November 18, 2009 - 12:47 -- Patrick Sampao
Author(s): 
Leah Mwai, Steven M. Kiara, Abdi Abdirahman, Lewa Pole, Anja Rippert, Abdi Diriye, Pete Bull, Kevin Marsh, Steffen Borrmann, and Alexis Nzila
Reference: 
Antimicrobial Agents and Chemotherapy, December 2009, p. 5069-5073, Vol. 53, No. 12, doi:10.1128/AAC.00638-09

We have analyzed the in vitro chemosensitivity profiles of 115 Kenyan isolates for chloroquine (CQ), piperaquine, lumefantrine (LM), and dihydroartemisinin in association with polymorphisms in pfcrt at codon 76 and pfmdr1 at codon 86, as well as with variations of the copy number of pfmdr1.

Medical Condition: 

Artemether Lumefantrine versus Dihydroartemisinin Piperaquine for Falciparum Malaria: A Longitudinal, Randomized Trial in Young Ugandan Children

November 16, 2009 - 14:04 -- Ingeborg van Schayk
Author(s): 
Emmanuel Arinaitwe, Taylor G. Sandison, Humphrey Wanzira, Abel Kakuru, Jaco Homsy, Julius Kalamya, Moses R. Kamya, Neil Vora, Bryan Greenhouse, Philip J. Rosenthal, Jordan Tappero, and Grant Dorsey
Reference: 
Clinical Infectious Diseases 2009; Volume 49, Number 11: Pages 1629–1637, DOI: 10.1086/647946

Artemisinin-based combination therapies are now widely recommended as first-line treatment for uncomplicated malaria. However, which therapies are optimal is a matter of debate. We aimed to compare the short- and longer-term efficacy of 2 leading therapies in a cohort of young Ugandan children.

Person: 
Country: 
Medical Condition: 

Review: Impact of the large-scale deployment of artemether/lumefantrine on the malaria disease burden in Africa: case studies of South Africa, Zambia and Ethiopia

October 25, 2009 - 15:39 -- Bart G.J. Knols
Author(s): 
Karen I Barnes, Pascalina Chanda, Gebre Ab Barnabas
Reference: 
Malaria Journal 2009, 8(Suppl 1):S8 (12 October 2009)

 

Malaria can be controlled in endemic countries by using artemisinin-based combination therapy (ACT) in combination with indoor residual spraying (IRS) and insecticide-treated nets (ITNs). At least 40 malaria-endemic countries in sub-Saharan Africa now recommend the use of ACT as first-line treatment for uncomplicated falciparum malaria as a cornerstone of their malaria case management.

Medical Condition: 

Review: Dispersible formulation of artemether/lumefantrine: specifically developed for infants and young children

October 25, 2009 - 15:25 -- Bart G.J. Knols
Author(s): 
Salim Abdulla, Issaka Sagara
Reference: 
Malaria Journal 2009, 8(Suppl 1):S7 (12 October 2009)

 

Ahead of a call from WHO for child-friendly medicines, Novartis, working in partnership with Medicines for Malaria Venture (MMV), started the development of a new formulation of AL for infants and young children: Coartem® Dispersible. 

Medical Condition: 

Review: Safety profile of Coartem®: the evidence base

October 25, 2009 - 15:17 -- Bart G.J. Knols
Author(s): 
Catherine Falade, Christine Manyando
Reference: 
Malaria Journal 2009, 8(Suppl 1):S6 (12 October 2009)

This article reviews the comprehensive data on the safety and tolerability from over 6,300 patients who have taken artemether/lumefantrine (Coartem®) as part of Novartis-sponsored or independently-sponsored clinical trials.

Medical Condition: 

Review: The clinical efficacy of artemether/lumefantrine (Coartem®)

October 25, 2009 - 15:12 -- Bart G.J. Knols
Author(s): 
Michael Makanga, Srivicha Krudsood
Reference: 
Malaria Journal 2009, 8(Suppl 1):S5 (12 October 2009)

 Current World Health Organization (WHO) guidelines for the treatment of uncomplicated falciparum malaria recommend the use of artemisinin-based combination therapy (ACT). Artemether/lumefantrine is an ACT prequalified by the WHO for efficacy, safety and quality, approved by Swissmedic in December 2008 and recently approved by the USA FDA. Coartem® is a fixed-dose combination of artemether and lumefantrine.

 

Medical Condition: 

Review: Understanding the pharmacokinetics of Coartem®

October 25, 2009 - 15:03 -- Bart G.J. Knols
Tags: 
Author(s): 
Abdoulaye Djimdé, Gilbert Lefèvre
Reference: 
Malaria Journal 2009, 8(Suppl 1):S4 (12 October 2009)

In conclusion, knowledge of the pharmacokinetic profiles of artemether and lumefantrine is increasing within a range of settings, including infants and children. However, additional data would be warranted to better characterize artemether and lumefantrine pharmacokinetics in patients with hepatic impairment, in pregnant women, and in patients undergoing HIV/AIDS chemotherapy.

 

Technology: 
Medical Treatment: 

Pages

Subscribe to RSS - lumefantrine